Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AMLX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Cash and Short Term Investments |
316.98 | 176.50 | 371.36 | 346.95 | 96.12 | 12.88 |
Receivables |
0.09 | 0.45 | 40.05 | 15.31 | — | — |
Inventory |
— | — | 38.32 | 9.77 | — | — |
Total current assets |
323.67 | 189.43 | 464.67 | 382.13 | 104.95 | 13.64 |
Property, Plant, Equpment (Net) |
0.31 | 0.96 | 2.69 | 2.61 | 0.47 | 0.15 |
Long-term assets (Other) |
3.48 | 1.47 | 1.42 | 1.19 | 0.19 | 0.31 |
Total non-current assets |
8.97 | 4.20 | 52.79 | 9.32 | 0.66 | 0.47 |
Total Assets |
332.65 | 193.63 | 517.45 | 391.45 | 105.61 | 14.10 |
Accounts Payable |
3.52 | 2.94 | 22.06 | 6.26 | 4.37 | 3.61 |
Accrued Expenses |
17.91 | 23.95 | 57.72 | 38.31 | 13.02 | 3.71 |
Total current liabilities |
22.69 | 28.41 | 82.04 | 46.61 | 17.40 | 7.33 |
Long Term Debt (Total) |
— | — | — | — | — | 1.43 |
Non-current Revenue (Deferred) |
— | — | — | — | 0.04 | 0.01 |
Non-current Liabilities (Other) |
— | — | — | — | — | 0.00 |
Total non-current liabilities |
4.70 | 0.46 | 1.98 | 4.24 | 0.04 | 1.44 |
Total liabilities |
27.39 | 28.87 | 84.02 | 50.85 | 17.43 | 8.77 |
Additional Paid In Capital |
1,056.27 | 771.54 | 738.18 | 694.91 | 4.67 | 1.19 |
Preferred Stock (Total) |
— | — | — | — | 239.35 | 72.06 |
Common Stock (Net) |
0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Retained Earnings |
(751.43) | (606.69) | (304.95) | (354.22) | (155.84) | (67.91) |
Common Equity (Total) |
305.26 | 164.77 | 433.43 | 340.61 | (151.17) | (66.72) |
Shareholders Equity (Total) |
305.26 | 164.77 | 433.43 | 340.61 | 88.18 | 5.34 |
Shareholders Equity and Liabilities (Total) |
332.65 | 193.63 | 517.45 | 391.45 | 105.61 | 14.10 |
Shares (Common) |
109.89 | 68.63 | 67.71 | 66.51 | 7.02 | 6.14 |
Shares (Preferred) |
— | — | — | — | 37.11 | 21.39 |
Shareholders Equity (Tangible) |
305.26 | 164.77 | 433.43 | 340.61 | 88.18 | 5.34 |
Net Debt |
(316.98) | (176.50) | (371.36) | (346.94) | (96.12) | (11.45) |
Total Debt |
— | — | — | — | — | 1.43 |